Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Agenus Inc.
  6. Summary
    AGEN   US00847G7051

AGENUS INC.

(AGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/17/2021 09/20/2021 09/21/2021 09/22/2021 09/23/2021 Date
5.83(c) 5.82(c) 5.81(c) 6.03(c) 6.08(c) Last
6 888 638 4 080 658 2 432 065 4 051 012 2 827 123 Volume
+4.67% -0.17% -0.17% +3.79% +0.83% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 263 M - -
Net income 2021 -95,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -13,8x
Yield 2021 -
Sales 2022 99,3 M - -
Net income 2022 -269 M - -
Net Debt 2022 - - -
P/E ratio 2022 -6,25x
Yield 2022 -
Capitalization 1 417 M 1 417 M -
Capi. / Sales 2021 5,38x
Capi. / Sales 2022 14,3x
Nbr of Employees 359
Free-Float 87,2%
More Financials
Company
Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody... 
More about the company
Ratings of Agenus Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about AGENUS INC.
09/17AGENUS : ESMO 2021 - Agenus Presents Updates on Balstilimab Plus Zalifrelimab Combination
PU
09/17ABCELLERA BIOLOGICS : Health Care Stocks Down to End Week
MT
09/17Health Care Stocks Mixed Premarket Friday
MT
09/17AGENUS : Says Cervical Cancer Combination Therapy Shows 'High' Response Rates in Phase 2 T..
MT
09/16Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in..
GL
09/14INSIDER SELL : Agenus
MT
09/10AGENUS : New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Co..
AQ
09/10Agenus Inc. Announces New Subsidiary, SaponiQx
CI
09/09AGENUS : to Participate in September Investor Conferences
AQ
09/07AGENUS : B. Riley Raises Agenus' PT to $12 from $11, Says Continued Regulatory Progress to..
MT
08/26AGENUS : Says Drug Shows Reduction in Cervical Cancer in Mid-Stage Study
MT
08/26AGENUS : Balstilimab Monotherapy Data Published in Gynecologic Oncology
AQ
08/26Agenus Inc. Announces Balstilimab Monotherapy Data Published in Gynecologic Oncology
CI
08/09AGENUS : Management's Discussion and Analysis of Financial Condition and Results of Operat..
AQ
08/09AGENUS : Posts Wider Q2 Loss, Lower Revenue
MT
More news
News in other languages on AGENUS INC.
09/17Les actions du secteur de la santé en baisse à la fin de la semaine
09/17Agenus déclare que la thérapie combinée contre le cancer du col de l'utérus présente de..
09/14VENTE D'INITIÉS : Agenus
2014Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on AGENUS INC.
More recommendations
Chart AGENUS INC.
Duration : Period :
Agenus Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AGENUS INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 6,08 $
Average target price 10,00 $
Spread / Average Target 64,5%
EPS Revisions
Managers and Directors
Garo H. Armen Chairman & Chief Executive Officer
Jennifer S. Buell President & Chief Operating Officer
Christine M. Klaskin Chief Financial & Accounting Officer, VP-Finance
Marc van Dijk Chief Technology Officer
Steven OĺDay Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AGENUS INC.91.20%1 417
MODERNA, INC.335.15%183 498
LONZA GROUP AG33.58%61 085
IQVIA HOLDINGS INC.46.38%50 254
CELLTRION, INC.-20.75%33 124
SEAGEN INC.-5.09%30 241